<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children - Cates, CJ - 2013 | Cochrane Library</title> <meta content="Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children - Cates, CJ - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007313.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children - Cates, CJ - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007313.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007313.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children" name="citation_title"/> <meta content="Christopher J Cates" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="ccates@sgul.ac.uk" name="citation_author_email"/> <meta content="Charlotta Karner" name="citation_author"/> <meta content="BMJ" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD007313.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/04/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007313.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007313.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007313.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenal Cortex Hormones [*administration &amp; dosage]; Anti‐Asthmatic Agents [*administration &amp; dosage]; Asthma [*drug therapy]; Bronchodilator Agents [administration &amp; dosage]; Budesonide [*administration &amp; dosage]; Chronic Disease; Drug Combinations; Ethanolamines [*administration &amp; dosage]; Formoterol Fumarate; Terbutaline [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007313.pub3&amp;doi=10.1002/14651858.CD007313.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tlnpj831";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007313\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007313\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007313.pub3",title:"Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children",firstPublishedDate:"Apr 30, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tlnpj831&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007313.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007313.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007313.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007313.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007313.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007313.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007313.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007313.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007313.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007313.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4322 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007313.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-sec-0098"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-sec-0093"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/appendices#CD007313-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/table_n/CD007313StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/table_n/CD007313StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/information#CD007313-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Christopher J Cates</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007313.pub3/information#CD007313-cr-0003">Charlotta Karner</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/information/en#CD007313-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 April 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007313.pub3">https://doi.org/10.1002/14651858.CD007313.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007313-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007313-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007313-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007313-abs-0005">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007313-abs-0001" lang="en"> <section id="CD007313-sec-0001"> <h3 class="title" id="CD007313-sec-0001">Background</h3> <p>Traditionally inhaled treatment for asthma has used separate preventer and reliever therapies. The combination of formoterol and budesonide in one inhaler has made possible a single inhaler for both prevention and relief of symptoms (single inhaler therapy or SiT). </p> </section> <section id="CD007313-sec-0002"> <h3 class="title" id="CD007313-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of budesonide and formoterol in a single inhaler for maintenance and reliever therapy in asthma compared with maintenance with inhaled corticosteroids (ICS) (alone or as part of current best practice) and any reliever therapy. </p> </section> <section id="CD007313-sec-0003"> <h3 class="title" id="CD007313-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group trials register in February 2013.</p> </section> <section id="CD007313-sec-0004"> <h3 class="title" id="CD007313-sec-0004">Selection criteria</h3> <p>Parallel, randomised controlled trials of 12 weeks or longer in adults and children with chronic asthma. Studies had to assess the combination of formoterol and budesonide as SiT, against a control group that received inhaled steroids and a separate reliever inhaler. </p> </section> <section id="CD007313-sec-0005"> <h3 class="title" id="CD007313-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD007313-sec-0006"> <h3 class="title" id="CD007313-sec-0006">Main results</h3> <p>We included 13 trials involving 13,152 adults and one of the trials also involved 224 children (which have been separately reported). All studies were sponsored by the manufacturer of the SiT inhaler. We considered the nine studies assessing SiT against best practice to be at a low risk of selection bias, but a high risk of detection bias as they were unblinded. </p> <p>In adults whose asthma was not well‐controlled on ICS, the reduction in hospital admission with SiT did not reach statistical significance (Peto odds ratio (OR) 0.81; 95% confidence interval (CI) 0.45 to 1.44, eight trials, N = 8841, low quality evidence due to risk of detection bias in open studies and imprecision). The rates of hospital admission were low; for every 1000 people treated with current best practice six would experience a hospital admission over six months compared with between three and eight treated with SiT. The odds of experiencing exacerbations needing treatment with oral steroids were lower with SiT compared with control (OR 0.83; 95% CI 0.70 to 0.98, eight trials, N = 8841, moderate quality evidence due to risk of detection bias). For every 100 adults treated with current best practice over six months, seven required a course of oral steroids, whilst for SiT there would be six (95% CI 5 to 7). The small reduction in time to first severe exacerbation needing medical intervention was not statistically significant (hazard ratio (HR) 0.94; 95% CI 0.85 to 1.04, five trials, N = 7355). Most trials demonstrated a reduction in the mean total daily dose of ICS with SiT (mean reduction was based on self‐reported data from patient diaries and ranged from 107 to 385 µg/day). Withdrawals due to adverse events were more common in people treated with SiT in comparison to current best practice (OR 2.85; 95% CI 1.89 to 4.30, moderate quality evidence due to risk of detection bias). </p> <p>Three studies including 4209 adults compared SiT with higher dose budesonide maintenance and terbutaline for symptom relief. The studies were considered as low risk of bias. The run‐in for these studies involved withdrawal of LABA, and patients were recruited who were symptomatic during run‐in. The reduction in the odds of hospitalisation with SiT compared with higher dose ICS did not reach statistical significance (Peto OR; 0.56; 95% CI 0.28 to 1.09, moderate quality evidence due to imprecision). Fewer patients on SiT needed a course of oral corticosteroids (OR 0.54; 95% CI 0.45 to 0.64, high quality evidence). For every 100 adults treated with ICS over 11 months, 18 required a course of oral steroids, whilst for SiT there would be 11 (95% CI 9 to 12). Withdrawals due to adverse events were less common in people treated with SiT in comparison to higher dose budesonide maintenance (OR 0.57; 95% CI 0.35 to 0.93, high quality evidence). </p> <p>One study included children (N = 224), in which SiT was compared with higher dose budesonide. There was a significant reduction in participants who needed an increase in their inhaled steroids with SiT, but there were only two hospitalisations for asthma and no separate data on courses of oral corticosteroids. Less inhaled and oral corticosteroids were used in the SiT group and the annual height gain was also 1 cm greater in the SiT group, (95% CI 0.3 cm to 1.7 cm). </p> <p>The results for fatal serious adverse events were too rare to rule out either treatment being harmful. There was no significant difference found in non‐fatal serious adverse events for any of the comparisons. </p> </section> <section id="CD007313-sec-0007"> <h3 class="title" id="CD007313-sec-0007">Authors' conclusions</h3> <p>Single inhaler therapy has now been demonstrated to reduce exacerbations requiring oral corticosteroids against current best practice strategies and against a fixed higher dose of inhaled steroids. The strength of evidence that SiT reduces hospitalisation against these same treatments is weak. There were more discontinuations due to adverse events on SiT compared to current best practice, but no significant differences in serious adverse events. Our confidence in these conclusions is limited by the open‐label design of the trials, and by the unknown adherence to treatment in the current best practice arms of the trials. </p> <p>Single inhaler therapy can reduce the risk of asthma exacerbations needing oral corticosteroids in comparison with fixed dose maintenance ICS and separate relief medication. The reduced odds of exacerbations with SiT compared with higher dose ICS should be viewed in the context of the possible impact of LABA withdrawal during study run‐in. This may have made the study populations more likely to respond to SiT. </p> <p>Single inhaler therapy is not currently licensed for children under 18 years of age in the United Kingdom and there is currently very little research evidence for this approach in children or adolescents. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007313-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007313-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007313-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007313-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007313-abs-0003" lang="en"> <h3>In people with asthma are single inhalers that contain both formoterol and budesonide better than current best practice? </h3> <p><b>Background to the review</b> <br/> ‘Single inhaler therapy’ means that a single inhaler containing two drugs is used. One of these drugs acts quickly and is called the "reliever". The other works much more slowly and is called the "preventer". The reliever is a beta‐agonist bronchodilator, which help to open the airways and help people breathe more easily. The preventer is a steroid that controls the underlying inflammation in the lungs, which is caused by the asthma. People on 'single inhaler therapy' (SiT) have one inhaler for use every day to control their underlying inflammation and also for symptom relief. The idea behind SiT is that when people take their inhalers to reduce their shortness of breath or wheezing they will also be getting an increased dose of the steroid preventer. </p> <p>We wanted to discover whether using the SiT was better or worse than alternatives, such as receiving two separate inhalers for regular treatment and relief of symptoms.<br/> <br/> <b>What did we do?</b> <br/> We reviewed the clinical trials that looked at SiT against inhaled steroids and reliever medication given as two separate inhalers (sometimes called current best practice).<br/> <br/> <b>What did we find out?</b> <br/> We found 13 trials on 13,152 adults and one trial also included 224 children, up to February 2013. The trials were all sponsored by the manufacturer of the single inhaler.<br/> <br/> When compared with current best practice or higher doses of inhaled steroid, we found that SiT probably reduces the number of flare‐ups that will need treatment with an oral steroid in adults but we are uncertain whether the number of adults admitted to hospital would be reduced. When compared with high doses of inhaled steroids, we found that fewer people experienced a flare‐up that needed treatment with an oral steroid.<br/> <br/> The results for death (1 per 1000 people given either treatment), or life threatening problems (just under 50 per 1000 people given either treatment), were too imprecise to enable us to rule out either treatment being more harmful than the other. More adults left the trial early because they experienced adverse effects in the group taking single inhalers. There was only one small trial in children, so we are unable to make any firm conclusions in children.<br/> <br/> The studies were generally well‐designed, although in the studies which compared SiT against current best practice people knew which treatment they were getting, and this could have affected the reliability of the results. The studies comparing SiT against inhaled steroids were designed differently and were more reliable. Overall, we think that more evidence from future trials might change the strength of the conclusions for the question of whether SiT is better than current best practice. We believe that there is good quality evidence that SiT is more effective than high dose inhaled steroids, although the studies recruited people who were likely to respond. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007313-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007313-sec-0098"></div> <h3 class="title" id="CD007313-sec-0099">Implications for practice</h3> <section id="CD007313-sec-0099"> <p>Guidelines suggest the addition of regular LABA or increasing the dose of ICS for asthma that is not controlled on regular low dose ICS. SiT did not significantly reduce exacerbations leading to hospitalisation in comparison with current best practice. However, SiT can reduce the risk of asthma exacerbations needing oral corticosteroids in comparison with fixed dose maintenance ICS, and to a lesser degree in comparison with current best practice in adults who were not well controlled on regular corticosteroids. There were more discontinuations due to adverse events on SiT compared with current best practice, but no significant differences in fatal or non‐fatal serious adverse events. </p> <p>Our confidence in these conclusions is limited by the open‐label design of the trials that compared SiT with current best practice, and by the reliability of the self‐reporting of adherence to treatment in the trials. The main limitation of the results from studies comparing SiT with higher dose inhaled steroids was the possible selection of participants with diminished asthma control following the withdrawal of LABA during run‐in. </p> <p>SiT is not currently licensed for children under 18 years of age in the United Kingdom and there is currently very little research evidence for this approach in children or adolescents. </p> </section> <h3 class="title" id="CD007313-sec-0100">Implications for research</h3> <section id="CD007313-sec-0100"> <p>More research is required on the efficacy and safety of SiT in children and adolescents, and on adults whose asthma is well‐controlled on low or moderate doses of ICS without additional LABA. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007313-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007313-sec-0015"></div> <div class="table" id="CD007313-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">160/4.5 mcg BDF single inhaler therapy compared to current best practice for adult asthma that is not controlled on ICS</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>160/4.5</b> µg<b>BDF single inhaler therapy compared to current best practice for adults with asthma that is not controlled on ICS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with asthma that is not controlled on ICS<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> 160/4.5 µg BDF single inhaler therapy<br/> <b>Comparison:</b> current best practice </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Current best practice</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> 160/4.5 µgBDF single inhaler therapy </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations causing hospitalisation</b> <br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/> (3 to 8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.81</b> <br/> (0.45 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8841<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations treated with oral steroids</b> <br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> <br/> (50 to 69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.83</b> <br/> (0.70 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8841<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatal serious adverse events</b> <br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> <br/> (0 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.95</b> <br/> (0.53 to 7.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8841<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (non‐fatal)</b> <br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> <br/> (18 to 32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.20</b> <br/> (0.90 to 1.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8841<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Discontinuation due to adverse events</b> <br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> <br/> (14 to 31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.85</b> <br/> (1.89 to 4.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8411<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unblinded trials<br/> <sup>2</sup> Confidence interval cannot rule out important differences in either direction </p> <p>BDF: budesonide plus formoterol; ICS: inhaled corticosteroids</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007313-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Single inhaler therapy compared to fixed dose ICS for asthma in adults not controlled on regular ICS</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Single inhaler therapy compared to fixed dose ICS for asthma in adults not controlled on regular ICS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with asthma in adults not controlled on regular ICS<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> Single inhaler therapy<br/> <b>Comparison:</b> fixed dose ICS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fixed dose ICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Single inhaler therapy </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations causing hospitalisation</b> <br/> Follow‐up: mean 11 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (3 to 11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.56</b> <br/> (0.28 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4209<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations treated with oral steroids</b> <br/> Follow‐up: mean 11 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>107 per 1000</b> <br/> (90 to 124) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.54</b> <br/> (0.45 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4280<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatal serious adverse events</b> <br/> Follow‐up: mean 11 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> <br/> (0 to 4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.37</b> <br/> (0.05 to 2.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4209<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (non‐fatal)</b> <br/> Follow‐up: mean 11 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> <br/> (36 to 62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.97</b> <br/> (0.73 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4209<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Discontinuation due to adverse events</b> <br/> Follow‐up: mean 11 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> <br/> (13 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.57</b> <br/> (0.35 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2586<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Confidence interval cannot rule out important differences in either direction<br/> ICS: inhaled corticosteroids </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007313-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007313-sec-0016"></div> <section id="CD007313-sec-0017"> <h3 class="title" id="CD007313-sec-0017">Description of the condition</h3> <p>There is currently no universally accepted definition of the term 'asthma'. This is in part due to an overlap of symptoms with other diseases such as chronic bronchitis, but is also due to the probable existence of more than one underlying pathophysiological process. There are, for example, wide variations in the age of onset, symptoms, triggers, association with allergic disease and the type of inflammatory cell infiltrate seen in patients diagnosed with asthma. Patients will typically all have intermittent symptoms of cough, wheeze, breathlessness or both. Underlying these symptoms there is a process of variable, at least partially reversible airway obstruction, airway hyper responsiveness and (with the possible exception of solely exercise‐induced asthma) chronic inflammation. </p> </section> <section id="CD007313-sec-0018"> <h3 class="title" id="CD007313-sec-0018">Description of the intervention</h3> <p>People with persistent asthma can use preventer therapy (usually low dose inhaled corticosteroid (ICS)) to maintain symptom control, improve lung function and reduce emergency care requirement. However, when symptoms deteriorate reliever medication in the form of short‐acting beta<sub>2</sub>‐agonists such as salbutamol or terbutaline, or formoterol (a fast‐acting but longer lasting formulation) can be used on an 'as‐needed' basis (<a href="./references#CD007313-bbs2-0054" title="Scottish Intercollegiate Guidelines Network/British Thoracic Society. British guideline on the management of asthma: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 2008 (revised 2012). ">SIGN/BTS 2012</a>). Since most exacerbations have an onset over several days (<a href="./references#CD007313-bbs2-0055" title="TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Tattersfield 1999</a>), there is potential for the person with asthma to increase both budesonide and formoterol at an early stage in response to increased symptoms of asthma. The pharmacological properties of another long‐acting beta<sub>2</sub>‐agonist (LABA), salmeterol, result in slower onset of bronchodilation (<a href="./references#CD007313-bbs2-0053" title="PalmqvistM , ArvidssonP , BeckmanO , PetersonS , LotvallJ . Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulmonary Pharmacology and Therapeutics2001;14(1):29‐34. ">Palmqvist 2001</a>), and it is not licensed for use on an 'as‐needed' basis. The inclusion of ICS in a reliever inhaler for use during episodes of loss of control requires monitoring and assessment of overall ICS dose (<a href="./references#CD007313-bbs2-0054" title="Scottish Intercollegiate Guidelines Network/British Thoracic Society. British guideline on the management of asthma: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 2008 (revised 2012). ">SIGN/BTS 2012</a>). </p> </section> <section id="CD007313-sec-0019"> <h3 class="title" id="CD007313-sec-0019">How the intervention might work</h3> <p>The combination of ICS and LABA in one inhaler is an effective way of delivering maintenance anti‐inflammatory and bronchodilator therapy in chronic asthma (<a href="./references#CD007313-bbs2-0042" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2] ">Ducharme 2010</a>; <a href="./references#CD007313-bbs2-0043" title="DucharmeFM , LassersonTJ , CatesCJ . Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD003137.pub4] ">Ducharme 2011</a>; <a href="./references#CD007313-bbs2-0051" title="Ni ChroininM , GreenstoneIR , DanishA , MagdolinosH , MasseV , ZhangX , et al. Long‐acting beta2‐agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD005535] ">Ni Chroinin 2005</a>; <a href="./references#CD007313-bbs2-0052" title="Ni ChroininM , LassersonTJ , GreenstoneI , DucharmeFM . Addition of long‐acting beta‐agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2009, issue 3. [DOI: 10.1002/14651858.CD007949] ">Ni Chroinin 2009</a>). The anti‐inflammatory properties of the ICS and the bronchodilatory effect of the LABA play complementary roles in reducing inflammation in the airways and improving lung function with relief of symptoms related to bronchospasm (<a href="./references#CD007313-bbs2-0030" title="AdamsNP , BestallJC , LassersonTJ , JonesPW , CatesCJ . Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4] ">Adams 2008</a>; <a href="./references#CD007313-bbs2-0057" title="WaltersEH , GibsonPG , LassersonTJ , WaltersJAE . Long‐acting beta2‐agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001385.pub2] ">Walters 2007</a>). Both are recommended when low dose ICS alone is not sufficient to control asthma, which is at step three in British asthma guidelines (<a href="./references#CD007313-bbs2-0054" title="Scottish Intercollegiate Guidelines Network/British Thoracic Society. British guideline on the management of asthma: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 2008 (revised 2012). ">SIGN/BTS 2012</a>). Concerns have been raised about the use of single inhaler LABA in chronic asthma, in particular where it is used without a regular ICS, in relation to the possible increased risk of severe adverse events and asthma‐related death (<a href="./references#CD007313-bbs2-0033" title="CatesCJ , CatesMJ . Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2] ">Cates 2008</a>; <a href="./references#CD007313-bbs2-0036" title="CatesCJ , LassersonTJ . Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD007694.pub2; CD007694] ">Cates 2010a</a>; <a href="./references#CD007313-bbs2-0038" title="CatesCJ , CatesMJ . Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD006923.pub3] ">Cates 2012a</a>; <a href="./references#CD007313-bbs2-0039" title="CatesCJ , LassersonTJ . Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD007695.pub3] ">Cates 2012b</a>; <a href="./references#CD007313-bbs2-0057" title="WaltersEH , GibsonPG , LassersonTJ , WaltersJAE . Long‐acting beta2‐agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001385.pub2] ">Walters 2007</a>). The concomitant delivery of ICS and LABA avoids the inadvertent use of LABA without prescribed ICS treatment (<a href="./references#CD007313-bbs2-0034" title="CatesCJ , LassersonTJ , JaeschkeR . Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006922.pub2] ">Cates 2009a</a>; <a href="./references#CD007313-bbs2-0035" title="CatesCJ , LassersonTJ , JaeschkeR . Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD006924.pub2] ">Cates 2009b</a>). </p> </section> <section id="CD007313-sec-0020"> <h3 class="title" id="CD007313-sec-0020">Why it is important to do this review</h3> <p>It is recognised that many patients who are prescribed ICS do not take their inhaler every day, and combination inhalers can increase ICS use both as maintenance (<a href="./references#CD007313-bbs2-0040" title="DeleaTE , HagiwaraM , StanfordRH , StempelDA . Effects of fluticasone propionate/salmeterol combination on asthma‐related health care resource utilization and costs and adherence in children and adults with asthma. Clinical Therapeutics2008; Vol. 30, issue 3:560‐71. ">Delea 2008</a>) and single inhaler therapy (SiT) (<a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a>). Whilst the trials that have investigated doubling the dose of ICS early in exacerbations have been disappointing (<a href="./references#CD007313-bbs2-0044" title="FitzGeraldJM , BeckerA , SearsMR , MinkS , ChungK , LeeJ . Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax2004; Vol. 59, issue 7:550‐6. ">FitzGerald 2004</a>; <a href="./references#CD007313-bbs2-0046" title="HarrisonT , OborneJ , NewtonS , TattersfieldA . Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet2004; Vol. 363, issue 9405:271‐5. ">Harrison 2004</a>), there is the potential with SiT for the patient to automatically increase both LABA and ICS when their asthma is worse and cut down again as their symptoms improve. This holds out the prospect of maintaining control of asthma and preventing exacerbations with lower overall exposure to ICS. </p> <p>This review has identified and summarised clinical trials that compare SiT for maintenance and relief with budesonide/formoterol against maintenance with ICS and a separate reliever therapy. The 2013 update to this review now includes data from an additional 4556 adults from trials comparing SiT with current best practice. The comparison of budesonide/formoterol for maintenance and relief against a higher dose maintenance ICS/LABA combination inhaler and a separate reliever therapy will be covered in another review (<a href="./references#CD007313-bbs2-0037" title="CatesCJ , LassersonTJ . Combination formoterol and inhaled steroid as maintenance and reliever therapy versus higher dose combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009019] ">Cates 2011</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007313-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007313-sec-0021"></div> <p>To assess the efficacy and safety of budesonide and formoterol in a single inhaler for maintenance and reliever therapy in asthma compared with maintenance with inhaled corticosteroids (alone or as part of current best practice) and any reliever therapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007313-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007313-sec-0022"></div> <section id="CD007313-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007313-sec-0024"> <h4 class="title">Types of studies</h4> <p>Randomised trials of parallel group design.</p> </section> <section id="CD007313-sec-0025"> <h4 class="title">Types of participants</h4> <p>Adults and children with a diagnosis of chronic asthma. We accepted trialist‐defined asthma, recording the definition of asthma used in the studies, and the entry criteria. We did not include studies conducted in an emergency department setting. </p> </section> <section id="CD007313-sec-0026"> <h4 class="title">Types of interventions</h4> <section id="CD007313-sec-0027"> <h5 class="title">Eligible treatment group intervention</h5> <p>Combined inhaled steroid and long‐acting beta<sub>2</sub>‐agonist (LABA) delivered through a single inhaler device for regular maintenance and the relief of asthma symptoms. </p> </section> <section id="CD007313-sec-0028"> <h5 class="title">Eligible control group treatment</h5> <p>Inhaled corticosteroid given as regular maintenance treatment with a separate reliever inhaler. This included "current best practice" according to local or international guidelines (which included an inhaled corticosteroid, <a href="./references#CD007313-bbs2-0045" title="From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2006. http://www.ginasthma.org(accessed 2006). ">GINA 2006</a>). </p> <p>We included studies lasting at least 12 weeks.</p> <p>We did not consider studies that compared different combination therapy inhalers (regular fluticasone/salmeterol versus regular budesonide/formoterol has been reviewed elsewhere <a href="./references#CD007313-bbs2-0049" title="LassersonTJ , CatesCJ , FerraraG , CasaliL . Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD004106.pub3] ">Lasserson 2008</a>), or titration of maintenance dosing of combination therapy based on clinical signs and symptoms. Trials randomising participants to SiT versus a fixed dose combination inhaler are included in another review (<a href="./references#CD007313-bbs2-0037" title="CatesCJ , LassersonTJ . Combination formoterol and inhaled steroid as maintenance and reliever therapy versus higher dose combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009019] ">Cates 2011</a>). </p> </section> </section> <section id="CD007313-sec-0029"> <h4 class="title">Types of outcome measures</h4> <section id="CD007313-sec-0030"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007313-list-0001"> <li> <p>Patients with exacerbations requiring hospitalisation</p> </li> <li> <p>Patients with exacerbations requiring oral corticosteroids</p> </li> <li> <p>Serious adverse events (including mortality and life‐threatening events)</p> </li> <li> <p>Growth (in children)</p> </li> </ul> </p> </section> <section id="CD007313-sec-0031"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007313-list-0002"> <li> <p>Severe exacerbations (composite outcome of hospitalisation/emergency room (ER) visit/oral steroid course) </p> </li> <li> <p>Diary card morning and evening peak expiratory flow (PEF)</p> </li> <li> <p>Clinic spirometry (FEV<sub>1</sub>) </p> </li> <li> <p>Number of rescue medication puffs required per day</p> </li> <li> <p>Symptoms/symptom‐free days</p> </li> <li> <p>Nocturnal awakenings</p> </li> <li> <p>Quality of life</p> </li> </ul> </p> </section> </section> </section> <section id="CD007313-sec-0032"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007313-sec-0033"> <h4 class="title">Electronic searches</h4> <p>Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (see <a href="./appendices#CD007313-sec-0104">Appendix 1</a> for further details). All records in the Specialised Register coded as 'asthma' were searched using the following terms: </p> <p>("single inhaler therapy" or SiT or SMART or relie* or "as need*" or as‐need* or prn or flexible or titrat*) and ((combin* or symbicort or viani) or ((steroid* or corticosteroid* or ICS or budesonide or BUD or Pulmicort or beclomethasone or BDP or becotide) and ("beta*agonist" or "beta*adrenergic agonist" or formoterol or eformoterol or oxis or foradil))) </p> <p>Date of last search was February 2013.</p> </section> <section id="CD007313-sec-0034"> <h4 class="title">Searching other resources</h4> <p>We contacted trialists and manufacturers to confirm data and establish whether other unpublished or ongoing studies were available for assessment. We handsearched clinical trials web sites (www.clinicaltrials.gov and www.fda.gov) and the clinical trial web sites of combination inhaler manufacturers (www.ctr.gsk.co.uk; www.astrazenecaclinicaltrials.com). </p> </section> </section> <section id="CD007313-sec-0035"> <h3 class="title" id="CD007313-sec-0035">Data collection and analysis</h3> <section id="CD007313-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Following electronic literature searches, two review authors (CC &amp; TL or CK) independently selected articles on the basis of title and/or abstract for full text scrutiny. The authors agreed a list of articles which were retrieved, and subsequently assessed each study to determine whether it was a secondary publication of a primary study publication, and to determine whether the study met the entry criteria of the review. </p> </section> <section id="CD007313-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>We extracted information from each study for the following characteristics.</p> <p> <ul id="CD007313-list-0003"> <li> <p>Design (description of randomisation, blinding, number of study centres and location, number of study withdrawals) </p> </li> <li> <p>Participants (N, mean age, age range of the study, gender ratio, baseline lung function, % on maintenance ICS or ICS/LABA combination &amp; average daily dose of steroid (BDP (beclomethasone dipropionate) equivalent), entry criteria) </p> </li> <li> <p>Intervention (type and dose of component ICS and LABA, control limb dosing schedule, intervention limb dose adjustment schedule, inhaler device, study duration and run‐in) </p> </li> <li> <p>Outcomes (type of outcome analysis, outcomes analysed)</p> </li> </ul> </p> <p>We summarised baseline severity of lung function and persistence of symptoms, and collected data on pre‐study maintenance therapies. </p> </section> <section id="CD007313-sec-0038"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed trial bias protection in the following domains study quality according to whether studies meet the following pre‐specified quality criteria (as met, unmet or unclear, <a href="./references#CD007313-bbs2-0048" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] Available from: www.cochrane‐handbook.org. The Cochrane Collaboration, 2008. ">Higgins 2008</a>). </p> <p> <ul id="CD007313-list-0004"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding (performance bias and detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Incomplete reporting of results (selective reporting bias)</p> </li> </ul> </p> </section> <section id="CD007313-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <p>We extracted data for each of the outcomes considered by the review from the trial publication(s) or from correspondence with the trialist or manufacturer. Exacerbations were the primary outcome for this review and were reported by subtype (hospitalisation and courses of oral steroids), rather than just as a composite outcome. Serious adverse events were considered separately as fatal and non‐fatal events. </p> </section> <section id="CD007313-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <p>We sought to obtain data from the trial sponsors that was reported with patients (rather than events) as the unit of analysis for the primary outcomes. Some patients may have suffered more than one exacerbation over the course of the studies and these events would not have been independent. </p> </section> <section id="CD007313-sec-0041"> <h4 class="title">Data synthesis</h4> <p>Data were combined with RevMan 5.0, using a fixed‐effect mean difference (calculated as a weighted mean difference) for continuous data variables, and a fixed‐effect Odds Ratio for dichotomous variables. When zero cells were present for an outcome in any of the included studies the Peto Odds Ratio was used to combine the results as it does not require a continuity correction to be used. For the primary outcomes of exacerbations and serious adverse events, when a significant Odds Ratio was found, we calculated an number needed to treat (NNT) (benefit or harm) for the different levels of risk as represented by control group event rates over a specified time period using the pooled Odds Ratio and its confidence interval (<a href="./references#CD007313-bbs2-0056" title="Visual Rx. www.nntonline.net/visualrx/Accessed June 2012. ">Visual Rx</a>). </p> </section> <section id="CD007313-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We pooled data from adults and children in separate subgroups. Adult studies were considered as those that recruited participants from 18 years of age upwards. Adult and adolescent studies were considered as those that recruit participants from 12 years of age upwards. We considered participants in studies where the upper age limit was 12 years as children, and in studies where the upper age limit was 18 years as children and adolescents. Subgroup analyses were not possible in relation to asthma severity and degree of control of symptoms at baseline. </p> <p>We measured statistical variation between combined studies by the I<sup>2</sup> statistic (<a href="./references#CD007313-bbs2-0047" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). Where this exceeded 20%, we investigated the heterogeneity found, before deciding whether to combine the study results for the outcome. </p> </section> <section id="CD007313-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were planned on the basis of risk of bias in studies and methods of data analysis (fixed‐effect and random‐effects models). </p> <section id="CD007313-sec-0044"> <h5 class="title">'Summary of findings' tables</h5> <p>We applied methods recommended by the <a href="http://www.gradeworkinggroup.org/" target="_blank">GRADE working group</a> to rate the quality of evidence of SiT in adults. We present separate Summary of Findings tables for these two comparisons which also include estimates of the absolute effects based on the results of our analyses. We rated the quality of evidence for five main outcomes: </p> <p> <ol id="CD007313-list-0005"> <li> <p>Patients with exacerbations causing hospitalisation</p> </li> <li> <p>Patients with exacerbations treated with oral steroids</p> </li> <li> <p>Fatal serious adverse events</p> </li> <li> <p>Serious adverse events (non‐fatal)</p> </li> <li> <p>Discontinuation due to adverse events</p> </li> </ol> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007313-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007313-sec-0045"></div> <section id="CD007313-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD007313-sec-0047"> <h4 class="title">Results of the search</h4> <p>An updated search was carried out in February 2013 and identified 72 new abstracts (since the search in September 2008). These were independently assessed for inclusion by CJC and CK. Additionally, a new citation and two web‐reports were identified by handsearching the identifiers for the included studies (<a href="./references#CD007313-bbs2-0004" title="AstraZeneca(BN‐00S‐0011) . Symbicort single inhaler therapy for asthma in a general practice setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610351Accessed Jluy 2012. [NCT00235911] RiemersmaRA , PostmaD , van derMolenT . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Primary Care Respiratory Journal2012;21:50‐6. ">Riemersma (NCT00235911)</a> and <a href="./references#CD007313-bbs2-0001" title="AstraZeneca(D5890L00011) . A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as‐needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D5890L00011 Accessed December 12th 2012. [NCT00252863] ">DE‐SOLO</a>). One of the previously identified ongoing studies was excluded as it compared two different SiT regimens (EUROSMART or NCT00463866a). New reports were found on the AstraZenca web site for the five other studies comparing single inhaler therapy (SiT) with current best practice (<a href="./references#CD007313-bbs2-0003" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label,parallel‐group, multicentre study – PASSION Study [D5890L00016]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610707Accessed July 2012. [NCT00628758] ">PASSION</a>; <a href="./references#CD007313-bbs2-0004" title="AstraZeneca(BN‐00S‐0011) . Symbicort single inhaler therapy for asthma in a general practice setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610351Accessed Jluy 2012. [NCT00235911] RiemersmaRA , PostmaD , van derMolenT . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Primary Care Respiratory Journal2012;21:50‐6. ">Riemersma (NCT00235911)</a>; <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a>; <a href="./references#CD007313-bbs2-0013" title="AstraZeneca . STYLE ‐ A Comparison of Symbicort SMART (Symbicort Turbuhaler160/4,5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, open‐labelled, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610702Accessed July 2012. [NCT00252824] AstraZeneca(D5890L00014) . STYLE ‐ symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov2005:http://www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008]. ">STYLE</a>; <a href="./references#CD007313-bbs2-0014" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler 200/6 μg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, randomised, open, parallel group multicentre study. [D5890L00005]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610675Accessed July 2012. [NCT00259792] ">SYMPHONIE</a>) and paper publications were also identified for <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a> (Quirce 2011) and <a href="./references#CD007313-bbs2-0004" title="AstraZeneca(BN‐00S‐0011) . Symbicort single inhaler therapy for asthma in a general practice setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610351Accessed Jluy 2012. [NCT00235911] RiemersmaRA , PostmaD , van derMolenT . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Primary Care Respiratory Journal2012;21:50‐6. ">Riemersma (NCT00235911)</a> (Riemersma 2012). </p> <p>The search that was previously carried out in September 2008 included 198 citations. From these, 51 were retrieved as full text articles, representing 24 unique studies. There were originally 10 studies (21 citations) included in the review and 14 studies (31 citations) that were excluded. Full details are given in the lists of <a href="./references#CD007313-bbs1-0001" title="">Included studies</a> and <a href="./references#CD007313-bbs1-0002" title="">Excluded studies</a>. </p> </section> <section id="CD007313-sec-0048"> <h4 class="title">Included studies</h4> <p>Five adult studies contributed new outcome data on 4560 adults and adolescents comparing SiT with current best practice for the 2013 update (<a href="./references#CD007313-bbs2-0001" title="AstraZeneca(D5890L00011) . A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as‐needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D5890L00011 Accessed December 12th 2012. [NCT00252863] ">DE‐SOLO</a>; <a href="./references#CD007313-bbs2-0003" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label,parallel‐group, multicentre study – PASSION Study [D5890L00016]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610707Accessed July 2012. [NCT00628758] ">PASSION</a>; <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a>; <a href="./references#CD007313-bbs2-0013" title="AstraZeneca . STYLE ‐ A Comparison of Symbicort SMART (Symbicort Turbuhaler160/4,5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, open‐labelled, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610702Accessed July 2012. [NCT00252824] AstraZeneca(D5890L00014) . STYLE ‐ symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov2005:http://www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008]. ">STYLE</a>; <a href="./references#CD007313-bbs2-0014" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler 200/6 μg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, randomised, open, parallel group multicentre study. [D5890L00005]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610675Accessed July 2012. [NCT00259792] ">SYMPHONIE</a>). Furthermore, new data on the characteristics of <a href="./references#CD007313-bbs2-0004" title="AstraZeneca(BN‐00S‐0011) . Symbicort single inhaler therapy for asthma in a general practice setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610351Accessed Jluy 2012. [NCT00235911] RiemersmaRA , PostmaD , van derMolenT . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Primary Care Respiratory Journal2012;21:50‐6. ">Riemersma (NCT00235911)</a> are now available, indicating that this study recruited participants with well‐controlled asthma (FEV<sub>1</sub> was nearly 100% predicted), and used a lower dose of budesonide/formoterol than the other studies comparing SiT with current best practice. This trial has therefore been considered in a separate comparison for the 2013 update. All of the included studies were sponsored or supported by AstraZeneca, the manufacturers of Symbicort. </p> <p>Thirteen studies involved 13,152 adults and adolescents, and one study also recruited children (<a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a>). The results from the 224 children included in the STAY study were reported in a separate paper by Bisgaard 2006. This has therefore been regarded separately from <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a>, which reported the adult results from the STAY study. </p> <section id="CD007313-sec-0049"> <h5 class="title">Intervention</h5> <p>The active treatment in most studies was budesonide/formoterol 160/4.5 µg one inhalation twice daily plus as‐needed; this is the delivered dose and is the same as 200/6 µg actuator dose described in some of the studies. In <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a> and <a href="./references#CD007313-bbs2-0004" title="AstraZeneca(BN‐00S‐0011) . Symbicort single inhaler therapy for asthma in a general practice setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610351Accessed Jluy 2012. [NCT00235911] RiemersmaRA , PostmaD , van derMolenT . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Primary Care Respiratory Journal2012;21:50‐6. ">Riemersma (NCT00235911)</a>, the maintenance treatment inhaler was 80/4.5 µg given as two inhalations in the evening, and in <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a>. The maintenance dose was budesonide/formoterol 80/4.5 µg one inhalation in the evening. </p> <p>Of the 13 adult studies, nine studies compared SiT with current best practice; these were <a href="./references#CD007313-bbs2-0001" title="AstraZeneca(D5890L00011) . A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as‐needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D5890L00011 Accessed December 12th 2012. [NCT00252863] ">DE‐SOLO</a>; <a href="./references#CD007313-bbs2-0002" title="AstraZeneca(D5890L00008) . MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00242411 [Accessed 12/04/2006]. ">MONO</a>; <a href="./references#CD007313-bbs2-0004" title="AstraZeneca(BN‐00S‐0011) . Symbicort single inhaler therapy for asthma in a general practice setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610351Accessed Jluy 2012. [NCT00235911] RiemersmaRA , PostmaD , van derMolenT . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Primary Care Respiratory Journal2012;21:50‐6. ">Riemersma (NCT00235911)</a>; <a href="./references#CD007313-bbs2-0003" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label,parallel‐group, multicentre study – PASSION Study [D5890L00016]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610707Accessed July 2012. [NCT00628758] ">PASSION</a>; <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a>; <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a>; <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a>; <a href="./references#CD007313-bbs2-0013" title="AstraZeneca . STYLE ‐ A Comparison of Symbicort SMART (Symbicort Turbuhaler160/4,5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, open‐labelled, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610702Accessed July 2012. [NCT00252824] AstraZeneca(D5890L00014) . STYLE ‐ symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov2005:http://www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008]. ">STYLE</a> and <a href="./references#CD007313-bbs2-0014" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler 200/6 μg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, randomised, open, parallel group multicentre study. [D5890L00005]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610675Accessed July 2012. [NCT00259792] ">SYMPHONIE</a>. In these studies long‐acting beta<sub>2</sub>‐agonists (LABA) were allowed in the control arm, and many of the participants were already using LABA when recruited. The only restriction on the current best practice group was that they must continue on inhaled corticosteroids (ICS). </p> <p>The other four studies compared SiT with ICS as maintenance and terbutaline as reliever (<a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a>; <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a>; <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a>; <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a>) and of these, the first three compared SiT with a higher dose of maintenance ICS. In these studies LABA were not allowed in the control arm, and were withdrawn from those patients previously taking them. <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a> compared to the same dose of ICS (as the main aim of this study was to assess compliance with ICS). </p> <p>The reported mean daily dose of ICS previously used by participants was reported as: <a href="./references#CD007313-bbs2-0002" title="AstraZeneca(D5890L00008) . MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00242411 [Accessed 12/04/2006]. ">MONO</a> (1035 µg), <a href="./references#CD007313-bbs2-0004" title="AstraZeneca(BN‐00S‐0011) . Symbicort single inhaler therapy for asthma in a general practice setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610351Accessed Jluy 2012. [NCT00235911] RiemersmaRA , PostmaD , van derMolenT . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Primary Care Respiratory Journal2012;21:50‐6. ">Riemersma (NCT00235911)</a> (538 µg); <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a> (579 µg), <a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a> (746 µg), <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a> (569 µg), <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a> (590 µg, but poor compliance was an inclusion criterion), <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a> (1034 µg, BDP equivalent), <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a> (660 µg), <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a> (315 µg), <a href="./references#CD007313-bbs2-0013" title="AstraZeneca . STYLE ‐ A Comparison of Symbicort SMART (Symbicort Turbuhaler160/4,5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, open‐labelled, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610702Accessed July 2012. [NCT00252824] AstraZeneca(D5890L00014) . STYLE ‐ symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov2005:http://www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008]. ">STYLE</a> (506 µg) and <a href="./references#CD007313-bbs2-0014" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler 200/6 μg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, randomised, open, parallel group multicentre study. [D5890L00005]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610675Accessed July 2012. [NCT00259792] ">SYMPHONIE</a> (792 µg). The mean daily dose was lower in <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a> (340 µg) and was not available from <a href="./references#CD007313-bbs2-0003" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label,parallel‐group, multicentre study – PASSION Study [D5890L00016]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610707Accessed July 2012. [NCT00628758] ">PASSION</a> or <a href="./references#CD007313-bbs2-0001" title="AstraZeneca(D5890L00011) . A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as‐needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D5890L00011 Accessed December 12th 2012. [NCT00252863] ">DE‐SOLO</a>. </p> <p>Inclusion criteria for <a href="./references#CD007313-bbs2-0001" title="AstraZeneca(D5890L00011) . A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as‐needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D5890L00011 Accessed December 12th 2012. [NCT00252863] ">DE‐SOLO</a>, <a href="./references#CD007313-bbs2-0002" title="AstraZeneca(D5890L00008) . MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00242411 [Accessed 12/04/2006]. ">MONO</a>, <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a>, <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a>, <a href="./references#CD007313-bbs2-0013" title="AstraZeneca . STYLE ‐ A Comparison of Symbicort SMART (Symbicort Turbuhaler160/4,5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, open‐labelled, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610702Accessed July 2012. [NCT00252824] AstraZeneca(D5890L00014) . STYLE ‐ symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov2005:http://www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008]. ">STYLE</a> and <a href="./references#CD007313-bbs2-0014" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler 200/6 μg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, randomised, open, parallel group multicentre study. [D5890L00005]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610675Accessed July 2012. [NCT00259792] ">SYMPHONIE</a> were that the participants had to be stable on a combination of LABA and ICS or symptomatic on ICS maintenance, and 82% of the participants used LABA at study entry with an average ICS dose of 979 µg/day (BDP equivalent). <a href="./references#CD007313-bbs2-0003" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label,parallel‐group, multicentre study – PASSION Study [D5890L00016]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610707Accessed July 2012. [NCT00628758] ">PASSION</a>, and <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a> required adults to be symptomatic on ICS maintenance (with or without LABA). <a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a>, <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a>, and <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a> included participants who had suffered a clinically important exacerbation in the previous year. In <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a>, 27% of patients were reported to have mild persistent asthma, 37% moderate persistent and 36% severe persistent. </p> <p>Some studies included a run‐in of about two weeks in which LABA was withdrawn (<a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a>; <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a>; <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a>; <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a>) and in the case of <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a>, the maintenance dose of ICS was reduced from an average of 350 µg/day to 200 µg/day as well, and in order to secure "a symptomatic population that could respond differently to different treatments, patients were required to have at least 7 inhalations of as‐needed medication during the last 10 days of the run‐in period". <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a> and <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a> continued usual therapy over the two‐week run‐in period, but details of any run‐in period are not currently available for the other studies. </p> </section> <section id="CD007313-sec-0050"> <h5 class="title">Outcomes</h5> <p>The primary outcomes for the studies are shown in the <a href="./references#CD007313-sec-0119" title="">Characteristics of included studies</a>. For the majority of studies this was time to first severe asthma exacerbation, which usually included hospitalisation, visits to an emergency department (ED), a course of oral steroids for the studies comparing with current best practice. Sometimes a 30% drop in peak expiratory flow (PEF) was also counted as an exacerbation, such as in <a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a>; <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a>; <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a>; <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a>. <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a> had a different design from the other studies and the primary outcome was the dose of ICS. </p> <p>All of the studies (apart from <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a>) are multicentre studies, and no information has been found in relation to differences between centres or countries in any of these trials. </p> </section> </section> <section id="CD007313-sec-0051"> <h4 class="title">Excluded studies</h4> <p>The reasons for the exclusion of 15 studies are documented in the <a href="./references#CD007313-sec-0120" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD007313-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>An overview of risk of bias judgements is shown in <a href="#CD007313-fig-0001">Figure 1</a> </p> <div class="figure" id="CD007313-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007313-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD007313-sec-0053"> <h4 class="title">Allocation</h4> <p><a href="./references#CD007313-bbs2-0041" title="DemolyP , LouisR , Soes‐PetersenU , NayaI , CarlsheimerA , WorthH , et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respiratory Medicine2009;103(11):1623‐32. ">Demoly 2009</a> has reported details for six of the included studies indicating low risk of allocation bias. As the rest of the trials were also sponsored by the same manufacturer, the risk of selection bias was assessed as low. </p> </section> <section id="CD007313-sec-0054"> <h4 class="title">Blinding</h4> <p>All the studies comparing SiT with current best practice were unblinded, and therefore were judged to be at high risk of performance and detection bias, whilst those comparing with higher doses of ICS were double‐blind and at low risk. <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a> was also unblinded as adherence was the primary outcome for this study. </p> </section> <section id="CD007313-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>There were imbalanced discontinuations in <a href="./references#CD007313-bbs2-0004" title="AstraZeneca(BN‐00S‐0011) . Symbicort single inhaler therapy for asthma in a general practice setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610351Accessed Jluy 2012. [NCT00235911] RiemersmaRA , PostmaD , van derMolenT . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Primary Care Respiratory Journal2012;21:50‐6. ">Riemersma (NCT00235911)</a>, <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a>, <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a> and <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a>, and around 20% discontinuations in each group in <a href="./references#CD007313-bbs2-0003" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label,parallel‐group, multicentre study – PASSION Study [D5890L00016]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610707Accessed July 2012. [NCT00628758] ">PASSION</a>. Othewise, the included studies were judged to be at low risk of attrition bias. </p> </section> <section id="CD007313-sec-0056"> <h4 class="title">Selective reporting</h4> <p>Missing data from five large trials on 4556 adults (<a href="./references#CD007313-bbs2-0001" title="AstraZeneca(D5890L00011) . A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as‐needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D5890L00011 Accessed December 12th 2012. [NCT00252863] ">DE‐SOLO</a>; <a href="./references#CD007313-bbs2-0003" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label,parallel‐group, multicentre study – PASSION Study [D5890L00016]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610707Accessed July 2012. [NCT00628758] ">PASSION</a>; <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a>; <a href="./references#CD007313-bbs2-0013" title="AstraZeneca . STYLE ‐ A Comparison of Symbicort SMART (Symbicort Turbuhaler160/4,5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, open‐labelled, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610702Accessed July 2012. [NCT00252824] AstraZeneca(D5890L00014) . STYLE ‐ symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov2005:http://www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008]. ">STYLE</a>; <a href="./references#CD007313-bbs2-0014" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler 200/6 μg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, randomised, open, parallel group multicentre study. [D5890L00005]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610675Accessed July 2012. [NCT00259792] ">SYMPHONIE</a>) comparing SiT with current best practice have been included in the 2013 update of this review. We are therefore now less concerned about missing trial reports in relation to the primary outcomes of this review. However, we have still not been able to obtain data from <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a> for the exacerbations requiring a course of oral corticosteroids. </p> </section> </section> <section id="CD007313-sec-0057"> <h3 class="title" id="CD007313-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD007313-tbl-0001"><b>Summary of findings for the main comparison</b> 160/4.5 mcg BDF single inhaler therapy compared to current best practice for adult asthma that is not controlled on ICS</a>; <a href="./full#CD007313-tbl-0002"><b>Summary of findings 2</b> Single inhaler therapy compared to fixed dose ICS for asthma in adults not controlled on regular ICS</a> </p> <p>The primary outcomes for this review were exacerbations leading to hospitalisation, exacerbations treated with a course of oral corticosteroids and serious adverse events. Initially the trials reported composite outcomes that include the above types of exacerbation combined with emergency room (ER) visits and sometimes a 30% drop in peak flow. We have obtained data on our primary outcomes from the trial sponsor and recent web reports (for the 2013 update). Most of the studies are also multi‐site randomised controlled trials and have not reported data from any of the individual sites. </p> <section id="CD007313-sec-0058"> <h4 class="title">Adults and adolescents treated with 160/4.5 µg single inhaler therapy (SiT) (twice daily and as‐needed) versus current best practice </h4> <p>Eight trials on 8841 adults and adolescents now contribute to this comparison for the 2013 update (<a href="./references#CD007313-bbs2-0001" title="AstraZeneca(D5890L00011) . A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as‐needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D5890L00011 Accessed December 12th 2012. [NCT00252863] ">DE‐SOLO</a>; <a href="./references#CD007313-bbs2-0002" title="AstraZeneca(D5890L00008) . MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00242411 [Accessed 12/04/2006]. ">MONO</a>; <a href="./references#CD007313-bbs2-0003" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label,parallel‐group, multicentre study – PASSION Study [D5890L00016]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610707Accessed July 2012. [NCT00628758] ">PASSION</a>; <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a>; <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a>; <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a>; <a href="./references#CD007313-bbs2-0013" title="AstraZeneca . STYLE ‐ A Comparison of Symbicort SMART (Symbicort Turbuhaler160/4,5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, open‐labelled, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610702Accessed July 2012. [NCT00252824] AstraZeneca(D5890L00014) . STYLE ‐ symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov2005:http://www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008]. ">STYLE</a>; <a href="./references#CD007313-bbs2-0014" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler 200/6 μg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, randomised, open, parallel group multicentre study. [D5890L00005]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610675Accessed July 2012. [NCT00259792] ">SYMPHONIE</a>). All of these studies ran for six months and recruited participants whose asthma was not controlled in spite of regular inhaled corticosteroids, or who were on treatment with LABA and ICS at recruitment (around 80% of those recruited). We have presented the quality of evidence for relevant outcomes in <a href="./full#CD007313-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD007313-sec-0059"> <h5 class="title">Primary outcomes</h5> <section id="CD007313-sec-0060"> <h6 class="title">Exacerbations of asthma causing hospital admissions</h6> <p>There were 47 people who suffered one or more hospitalisations from a total of 8841 participants in the eight trials providing data for this outcome (21 in the SiT arms and 26 in the current best practice arms). <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a> reported two asthma exacerbations that required hospitalisation in the SiT arm of the study, and we have obtained confirmation from the sponsors that the two events were in separate participants. There was no significant difference in the pooled outcome: (Peto odds ratio (OR) 0.81; 95% confidence interval (CI) 0.45 to 1.44; low quality evidence due to risk of bias and imprecision), see <a href="#CD007313-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD007313-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Conventional Best Practice, outcome: 1.1 Patients with exacerbations causing hospitalisation." data-id="CD007313-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Conventional Best Practice, outcome: 1.1 Patients with exacerbations causing hospitalisation. </p> </div> </div> </div> </section> <section id="CD007313-sec-0061"> <h6 class="title">Exacerbations of asthma treated with oral corticosteroids</h6> <p>We originally obtained data from four studies (<a href="./references#CD007313-bbs2-0002" title="AstraZeneca(D5890L00008) . MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00242411 [Accessed 12/04/2006]. ">MONO</a>, <a href="./references#CD007313-bbs2-0004" title="AstraZeneca(BN‐00S‐0011) . Symbicort single inhaler therapy for asthma in a general practice setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610351Accessed Jluy 2012. [NCT00235911] RiemersmaRA , PostmaD , van derMolenT . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Primary Care Respiratory Journal2012;21:50‐6. ">Riemersma (NCT00235911)</a>, <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a> and <a href="./references#CD007313-bbs2-0013" title="AstraZeneca . STYLE ‐ A Comparison of Symbicort SMART (Symbicort Turbuhaler160/4,5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, open‐labelled, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610702Accessed July 2012. [NCT00252824] AstraZeneca(D5890L00014) . STYLE ‐ symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov2005:http://www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008]. ">STYLE</a>, 4470 participants) on patients with one or more courses of oral corticosteroids and the reduction with SiT was not significant at that time (OR 0.83; 95% CI 0.66 to 1.03; moderate quality evidence due to risk of bias). </p> <p>However, with the update in 2013 there are now eight trials on 8841 participants contributing to the meta‐analysis and with the new data the reduction with SiT is now statistically significant (OR 0.83; 95% CI 0.70 to 0.98) see <a href="#CD007313-fig-0003">Figure 3</a>. Three hundred and four out of 4408 participants (7%) were treated with oral corticosteroids using current best practice over six months, and this translates into a number needed to treat to benefit (NNTB) of 90 (95% CI 51 to 767), to prevent one patient needing oral corticosteroids over an 11‐month period, see <a href="#CD007313-fig-0004">Figure 4</a> </p> <div class="figure" id="CD007313-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 adults and adolescents treated with Single Inhaler Therapy versus Conventional Best Practice, outcome: 1.2 Patients with exacerbations treated with oral steroids." data-id="CD007313-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 adults and adolescents treated with Single Inhaler Therapy versus Conventional Best Practice, outcome: 1.2 Patients with exacerbations treated with oral steroids. </p> </div> </div> </div> <div class="figure" id="CD007313-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="In the current best practice group 7 people out of 100 had exacerbations treated with oral steroids over 6 months, compared to 6 (95% CI 5 to 7) out of 100 for the single inhaler therapy group. NNT(B) = 90, (95% CI: 51 to 767)." data-id="CD007313-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>In the current best practice group 7 people out of 100 had exacerbations treated with oral steroids over 6 months, compared to 6 (95% CI 5 to 7) out of 100 for the single inhaler therapy group. NNT(B) = 90, (95% CI: 51 to 767). </p> </div> </div> </div> </section> <section id="CD007313-sec-0062"> <h6 class="title">Serious adverse events</h6> <p>No significant difference was seen in people who suffered a fatal or non‐fatal serious adverse event from the combined results of the eight trials on 8841 participants; for fatal events (Peto OR 1.95; 95% CI 0.53 to 7.21; low quality evidence due to risk of bias and imprecision) <a href="./references#CD007313-fig-0010" title="">Analysis 1.3</a>, and for non‐fatal events (OR 1.20; 95% CI 0.90 to 1.60; low quality evidence due to risk of bias and imprecision) <a href="./references#CD007313-fig-0011" title="">Analysis 1.4</a>. However, the overall number of events was still too small to rule out the possibility of a clinically important increase or decrease in serious adverse events (as reflected in the wide confidence intervals). Peto OR was used for the fatal serious adverse events analysis in view of the presence of trials with no deaths in some of the treatment arms. </p> <p>A post‐hoc observation was that there was a higher number of discontinuations due to adverse events with SiT (OR 2.85; 95% CI 1.89 to 4.30; moderate quality evidence due to risk of bias), see <a href="./references#CD007313-fig-0012" title="">Analysis 1.5</a>. This finding was attributed by the investigators to patients in the SiT arm who changed from metered‐dose inhaler (MDI) to dry‐powder inhaler devices, and who were not allowed to change their maintenance treatment during the course of the study. </p> </section> </section> <section id="CD007313-sec-0063"> <h5 class="title">Secondary outcomes</h5> <section id="CD007313-sec-0064"> <h6 class="title">Severe exacerbations requiring medical intervention</h6> <p>There was no overall significant reduction in the time to a severe exacerbation, as defined by the investigators, which was the primary outcome measure for these trials (Hazard Ratio (HR) 0.94; 95% CI 0.85 to 1.04, seven studies, N = 7355), <a href="./references#CD007313-fig-0013" title="">Analysis 1.6</a>. The HR was not reported for <a href="./references#CD007313-bbs2-0001" title="AstraZeneca(D5890L00011) . A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as‐needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D5890L00011 Accessed December 12th 2012. [NCT00252863] ">DE‐SOLO</a>. </p> </section> <section id="CD007313-sec-0065"> <h6 class="title">Change in morning peak expiratory flow (PEF)</h6> <p>The change in morning PEF (% predicted) in <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a> was 1.00% (95% CI ‐0.96 to 2.96) which was in favour of SiT, but neither clinically nor statistically significant (<a href="./references#CD007313-fig-0014" title="">Analysis 1.7</a>). Data were not available for this outcome from <a href="./references#CD007313-bbs2-0002" title="AstraZeneca(D5890L00008) . MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00242411 [Accessed 12/04/2006]. ">MONO</a> and <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a>. </p> </section> <section id="CD007313-sec-0066"> <h6 class="title">Rescue medication use</h6> <p>There was a difference of ‐0.16 (95% CI ‐0.27 to ‐0.05) puffs per day of rescue medication use in the SiT arm of <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a> compared to current best practice, <a href="./references#CD007313-fig-0015" title="">Analysis 1.8</a>. </p> </section> <section id="CD007313-sec-0067"> <h6 class="title">Quality of life (change in ACQ score)</h6> <p>The five studies reporting this outcome had heterogeneous findings (<a href="./references#CD007313-fig-0016" title="">Analysis 1.9</a>). <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a>, <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a> and <a href="./references#CD007313-bbs2-0014" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler 200/6 μg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, randomised, open, parallel group multicentre study. [D5890L00005]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610675Accessed July 2012. [NCT00259792] ">SYMPHONIE</a> demonstrated an improvement in the ACQ score in favour of SiT, whilst in <a href="./references#CD007313-bbs2-0001" title="AstraZeneca(D5890L00011) . A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as‐needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D5890L00011 Accessed December 12th 2012. [NCT00252863] ">DE‐SOLO</a> and <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a> the direction of effect favoured current best practice. The results have not been combined in view of the heterogeneity (I<sup>2</sup> = 68%) . </p> </section> </section> <section id="CD007313-sec-0068"> <h5 class="title">Steroid load</h5> <p>Five studies demonstrated a significantly lower intake of inhaled steroids in the SiT arms in comparison with current best practice but again, heterogeneity was high (I<sup>2</sup> = 91%) and the results were therefore not combined. It is expected that the size of the reduction in ICS dose will reflect the trial design for each study, giving rise to the heterogeneity, and in the mean differences that ranged from 107 µg/day in <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a> to 267 µg/day in <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a> (<a href="./references#CD007313-fig-0017" title="">Analysis 1.10</a>). Data from <a href="./references#CD007313-bbs2-0014" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler 200/6 μg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, randomised, open, parallel group multicentre study. [D5890L00005]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610675Accessed July 2012. [NCT00259792] ">SYMPHONIE</a> indicates a mean difference of 549 µg/day, but this trial has not been reported in full and it is not clear whether this difference includes the inhaled steroid used "as required" in each arm. <a href="./references#CD007313-bbs2-0013" title="AstraZeneca . STYLE ‐ A Comparison of Symbicort SMART (Symbicort Turbuhaler160/4,5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, open‐labelled, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610702Accessed July 2012. [NCT00252824] AstraZeneca(D5890L00014) . STYLE ‐ symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov2005:http://www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008]. ">STYLE</a> also indicated a lower mean daily dose of ICS on SiT (472 versus 516 µg) but provides no variance data in the web report. Furthermore, some trials reported the differences as BDP equivalent doses (e.g. <a href="./references#CD007313-bbs2-0009" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised,open‐label, parallel‐group, multicentre study. Study SPAIN [D5890L00010]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610692Accessed July 2012. AstraZeneca . Symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults. http://clinicaltrials.gov/ct2/show/results/NCT00385593?sect=X30125#evnt Accessed December 12th 2012. [NCT00385593] QuirceS , BarcinaC , PlazaV , CalvoE , MunozM , AmpudiaR , et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. Journal of Asthma2011;48:839‐47. ">SPAIN</a>); this was not combined with the other trial results. </p> </section> </section> <section id="CD007313-sec-0069"> <h4 class="title">Adults treated with 80/4.5 µg single inhaler therapy (SiT) (two doses in the evening and as‐needed) versus current best practice </h4> <p>One trial on 102 adults was included for this comparison (<a href="./references#CD007313-bbs2-0004" title="AstraZeneca(BN‐00S‐0011) . Symbicort single inhaler therapy for asthma in a general practice setting. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610351Accessed Jluy 2012. [NCT00235911] RiemersmaRA , PostmaD , van derMolenT . Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Primary Care Respiratory Journal2012;21:50‐6. ">Riemersma (NCT00235911)</a>. The primary aim of the study was to assess bronchial hyper responsiveness in primary care in adults with mild to moderate persistent asthma who were well controlled on ICS (<a href="./references#CD007313-fig-0023" title="">Analysis 2.6</a>). </p> <p>The daily average dose of ICS was lower on the SiT arm (326 µg/day in comparison to 798 µg/day on usual care), but the number of participants with exacerbations and adverse events was too small to assess whether the treatments were equivalent or different for the primary outcomes of this review (<a href="./references#CD007313-fig-0018" title="">Analysis 2.1</a>; <a href="./references#CD007313-fig-0019" title="">Analysis 2.2</a>; <a href="./references#CD007313-fig-0020" title="">Analysis 2.3</a>; <a href="./references#CD007313-fig-0021" title="">Analysis 2.4</a>; <a href="./references#CD007313-fig-0022" title="">Analysis 2.5</a>). </p> </section> <section id="CD007313-sec-0070"> <h4 class="title">Adults and adolescents treated with single inhaler therapy (SiT) versus maintenance inhaled corticosteroids (ICS)with separate reliever inhaler </h4> <p>We have presented the quality of evidence for relevant outcomes in <a href="./full#CD007313-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD007313-sec-0071"> <h5 class="title">Primary outcomes</h5> <section id="CD007313-sec-0072"> <h6 class="title">Exacerbations of asthma causing hospital admissions</h6> <p><a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a>, <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a> and <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a> contributed 4209 participants to this outcome, and overall there were fewer admissions on SiT in comparison to ICS, but this was not statistically significant. The number of admitted patients was small (12 in total on SiT and 22 on ICS) and the pooled result is (Peto OR 0.56; 95% CI 0.28 to 1.09; moderate quality evidence due to imprecision), as shown in <a href="#CD007313-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD007313-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus higher fixed dose ICS, outcome: 2.1 Patients with exacerbations causing hospitalisation." data-id="CD007313-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus higher fixed dose ICS, outcome: 2.1 Patients with exacerbations causing hospitalisation. </p> </div> </div> </div> <p>The data used for <a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a> and <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a> were on file from AstraZeneca, and were reported as patients with at least one asthma‐aggravated serious adverse event that required hospitalisation. The composite outcome of hospitalisation or ED visits was dominated by participants attending ED and was therefore not used for this outcome. In total,17 patients were admitted to hospital in comparison to 38 seen in ED from these two studies. Peto OR was chosen for this meta‐analysis as this method does not require a continuity correction for zero cells. Sensitivity analysis using Mantel‐Haenszel OR gave very similar results (OR 0.56; 95% CI 0.28 to 1.11). </p> </section> <section id="CD007313-sec-0073"> <h6 class="title">Exacerbations of asthma treated with oral corticosteroids</h6> <p><a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a>, <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a>, <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a> and <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a> contributed data on this outcome from 4280 participants; unpublished data on file from AstraZeneca has been obtained from <a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a> and <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a>. The <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a> paper reported descriptive statistics only of courses of oral steroids per year, and in adults this was 0.19 on SiT and 0.38 on budesonide. The pooled result showed a significant reduction in the number of patients requiring a course of steroids (OR 0.54; 95% CI 0.45 to 0.64; high quality evidence) and with a total of 228 patients with an event on SiT and 387 on budesonide, <a href="#CD007313-fig-0006">Figure 6</a>. For every 100 adults treated with ICS over 11 months, 18 required a course of oral steroids, whilst for SiT there would be 11 (95% CI: 9 to 12), <a href="#CD007313-fig-0007">Figure 7</a>. This translates into a number needed to treat to prevent one patient needing oral corticosteroids over an 11‐month period of 14 (95% CI 12 to 18). </p> <div class="figure" id="CD007313-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 adults and adolescents treated with Single Inhaler Therapy versus higher fixed dose ICS, outcome: 2.2 Patients with exacerbations treated with oral steroids." data-id="CD007313-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 adults and adolescents treated with Single Inhaler Therapy versus higher fixed dose ICS, outcome: 2.2 Patients with exacerbations treated with oral steroids. </p> </div> </div> </div> <div class="figure" id="CD007313-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="In the fixed dose ICS group 18 people out of 100 had exacerbation treated with oral steroids over 11 months, compared to 11 (95% CI 9 to 12) out of 100 treated with single inhaler therapy. NNT(B) = 14, (95% CI 12 to 18)." data-id="CD007313-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>In the fixed dose ICS group 18 people out of 100 had exacerbation treated with oral steroids over 11 months, compared to 11 (95% CI 9 to 12) out of 100 treated with single inhaler therapy. NNT(B) = 14, (95% CI 12 to 18). </p> </div> </div> </div> <p>Sensitivity analysis using random‐effects Mantel‐Haenszel OR gave a marginally wider confidence interval (OR 0.54; 95% CI 0.44 to 0.65). The design of <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a> was different from the other studies in that adherence with ICSwas the primary concern of the study. </p> </section> <section id="CD007313-sec-0074"> <h6 class="title">Serious adverse events</h6> <p>No significant difference was seen in either fatal or non‐fatal serious adverse events from the combined results of <a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a>, <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a> and <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a>; for fatal events (Peto OR 0.37; 95% CI 0.05 to 2.62; moderate quality evidence due to imprecision), and for non‐fatal events (OR 0.97; 95% CI 0.73 to 1.29; moderate quality evidence due to imprecision). Again, the number of events was small (four fatal and 201 non‐fatal) so the confidence interval includes the possibility of important increase or decrease with SiT. </p> <p>In contrast to the studies comparing SiT to current best practice, a post hoc inspection of discontinuations due to adverse events in <a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a> and <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a> found a significant decrease in favour of SiT (OR 0.57; 95% CI 0.35 to 0.93; high quality evidence). </p> </section> </section> <section id="CD007313-sec-0075"> <h5 class="title">Secondary outcomes</h5> <section id="CD007313-sec-0076"> <h6 class="title">Severe exacerbations requiring medical intervention</h6> <p>There were 1301 on SiT compared with 1285 on twice the dose of budesonide in <a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a> and <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a>. There was a significant reduction in the time to a serious exacerbation, as defined by the investigators, (HR 0.59; 95% CI 0.49 to 0.70), <a href="./references#CD007313-fig-0029" title="">Analysis 3.6</a>. </p> </section> <section id="CD007313-sec-0077"> <h6 class="title">Change in morning peak expiratory flow (PEF) and clinic FEV<sub>1</sub> </h6> <p>There was a significant increase in PEF in the SiT arms of <a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a>, <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a> and <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a> compared to higher doses of budesonide (mean difference (MD) 22.29 L/min; 95% CI 17.62 to 26.95), <a href="./references#CD007313-fig-0030" title="">Analysis 3.7</a>. Similarly, an increase of FEV<sub>1</sub> in favour of SiT was found (MD 0.10 L ; 95% CI 0.07 to 0.13), <a href="./references#CD007313-fig-0031" title="">Analysis 3.8</a>. </p> </section> <section id="CD007313-sec-0078"> <h6 class="title">Rescue medication use</h6> <p>There was a reduction in rescue medication use in favour of SiT (MD ‐0.37 puffs per day; 95% CI ‐0.49 to ‐0.25), <a href="./references#CD007313-fig-0032" title="">Analysis 3.9</a>. </p> </section> <section id="CD007313-sec-0079"> <h6 class="title">Quality of life (change in ACQ score)</h6> <p>The only study reporting ACQ scores was <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a> and no significant difference was found, <a href="./references#CD007313-fig-0033" title="">Analysis 3.10</a>. </p> </section> </section> <section id="CD007313-sec-0080"> <h5 class="title">Steroid load</h5> <p><a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a> reported a mean daily budesonide dose of 466 µg/day in the SiT arm in comparison with 640 µg/day in the ICS arm, and 1776 days on oral corticosteroids in comparison with 3177 days. <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a> did not report the mean daily doses of budesonide, but reported 0.19 courses of oral corticosteroids per year for SiT compared to 0.38 per year for higher dose budesonide. <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a> reported a mean daily budesonide dose of 240 µg/day with SiT and 320 µg/day in the higher dose ICS arm. However, the paper also reported five patients on SiT who had a mean daily dose of &gt; 640 µg/day on SiT. Again, <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a> reported a total of 114 days of oral corticosteroids with SiT and 498 days with higher dose budesonide. </p> <p><a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a> was designed to investigate whether SiT could overcome poor adherence with ICS, and found an increase in mean daily use of budesonide (448 versus 252 µg/day, MD 196 µg/day, 95% CI 113 to 279 µg/day). </p> </section> </section> <section id="CD007313-sec-0081"> <h4 class="title">Children treated with single inhaler therapy (SiT) versus higher doses of inhaled corticosteroids (ICS) </h4> <section id="CD007313-sec-0082"> <h5 class="title">Primary outcomes</h5> <section id="CD007313-sec-0083"> <h6 class="title">Exacerbations of asthma causing hospital admissions</h6> <p>We obtained clarification from the sponsors in relation to the hospitalisations for children in each treatment arm of <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a>. Hospitalisations related to asthma were reported as none on SiT and one with ICS (this does not quite match the asthma serious adverse event data, as one child was already in hospital with laryngitis, and the stay was prolonged due to an asthma exacerbation) <a href="./references#CD007313-fig-0034" title="">Analysis 4.1</a>. These events were too few to draw any conclusions. </p> </section> <section id="CD007313-sec-0084"> <h6 class="title">Exacerbations of asthma treated with oral corticosteroids</h6> <p>The only information in the report of <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a> in relation to oral corticosteroid use relates to the total number of treatment days in each group (32 days for SiT and 141 days for ICS). This is not suitable for use in meta‐analysis as there is no report of how many children were treated with oral corticosteroids in each group. The sponsors have not been able to provide these data. </p> </section> <section id="CD007313-sec-0085"> <h6 class="title">Serious adverse events</h6> <p>There were no fatal serious adverse events in <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a> and non‐fatal events occurred in two out of 118 children on SiT compared with five out of 106 on ICS (a non‐significant reduction) <a href="./references#CD007313-fig-0036" title="">Analysis 4.3</a>. </p> </section> <section id="CD007313-sec-0086"> <h6 class="title">Annual height gain</h6> <p>The mean increase in height over one year in the SiT group was 5.3 cm (range 1 to 14 cm) and in the ICS group the mean increase was 4.3 cm (range ‐2 to 15 cm). The fact that some children appear to have become shorter raises concerns about the accuracy of the measurements carried out in some of the 246 centres (as the paper reports that local procedures were used to measure height), but the average advantage of 1 cm for SiT was statistically significant (95% CI 0.3 to 1.7 cms) <a href="./references#CD007313-fig-0037" title="">Analysis 4.4</a>. </p> </section> </section> <section id="CD007313-sec-0087"> <h5 class="title">Secondary outcomes</h5> <section id="CD007313-sec-0088"> <h6 class="title">Severe exacerbations requiring medical intervention</h6> <p>There were nine patients on SiT with exacerbations requiring medical intervention (hospitalisation or ER visit or course of oral steroids) which was significantly less than the 21 patients given ICS, (OR 0.33; 95% CI 0.15 to 0.77). </p> </section> <section id="CD007313-sec-0089"> <h6 class="title">Change in morning peak expiratory flow (PEF)</h6> <p>The children given SiT therapy in <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a> had an average increase in morning PEF of 12 L/min (95% CI 4.55 to 19.45) in comparison with those given ICS. </p> </section> <section id="CD007313-sec-0090"> <h6 class="title">Clinic spirometry (FEV<sub>1</sub>) </h6> <p>There was no significant difference in FEV<sub>1</sub> between the SiT and ICS groups in <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a> (0.10 L; 95% CI ‐0.14 to 0.34). </p> </section> <section id="CD007313-sec-0091"> <h6 class="title">Nocturnal awakenings</h6> <p>There were, on average, two less nocturnal awakenings per night for children on SiT than those on ICS in <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a> (‐2.00 [95% CI ‐3.33 to ‐0.67]). </p> </section> </section> <section id="CD007313-sec-0092"> <h5 class="title">Steroid load</h5> <p>The mean daily dose of budesonide in children given SiT in <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a> was 126 µg/day in comparison to 320 µg/day in the group randomised to fixed dose budesonide. There were also less days spent on oral corticosteroids in the SiT group (32 versus 141 days). Two of 51 children given SiT had abnormally low cortisol levels in comparison with three of 41 on ICS, a non‐significant reduction (OR 0.52; 95% CI 0.08 to 3.25). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007313-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007313-sec-0093"></div> <section id="CD007313-sec-0094"> <h3 class="title" id="CD007313-sec-0094">Summary of main results</h3> <p>In comparison to current best practice, which allowed the use of long‐acting beta<sub>2</sub>‐agonists (LABA) in the control arms, the updated evidence from eight trials on 841 adults and adolescents has not demonstrated significant advantages for SiT in exacerbations needing hospital admission (Peto OR 0.81; 95% CI 0.45 to 1.44), but has shown a significant reduction in exacerbations treated with a course of oral steroids (OR 0.83; 95% CI 0.70 to 0.98). For every 100 adults treated with current best practice over six months, seven required a course of oral steroids, whilst for SiT there would be six (95% CI 5 to 7), <a href="#CD007313-fig-0004">Figure 4</a>. There was no significant difference found in fatal or non‐fatal serious adverse events, nor in the hazard ratio (HR) of time to first exacerbation (HR 0.94; 95% CI 0.85 to 1.04). All the studies found a reduction in ICS dose when using SiT. </p> <p>In comparison to higher maintenance doses of budesonide (with no LABA in the control arms), four studies (<a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a>, <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a>, <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a> and <a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a>) involving 4280 patients demonstrated significant reductions in patients with an exacerbation needing oral steroids (OR 0.54; 95% CI 0.45 to 0.64). For every 100 adults treated with inhaled corticosteroids (ICS) over 11 months, 18 required a course of oral steroids, whilst for SiT there would be 11 (95% CI 9 to 12), <a href="#CD007313-fig-0007">Figure 7</a>. There was no significant reduction in exacerbations leading to hospitalisation (Peto OR 0.56; 95% CI 0.28 to 1.09). There was no significant difference found in fatal or non‐fatal serious adverse events. The studies also found a reduction in ICS dose when using SiT. </p> <p><a href="./references#CD007313-bbs2-0008" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a> demonstrated increased adherence with ICS using SiT in comparison to maintenance budesonide at the same dose. </p> <p>Only one study included 224 children (<a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a>) and compared SiT to four times the dose of regular budesonide. There was a significant reduction in exacerbations needing increase in inhaled steroid treatment, or additional treatment or both in this study, but there were only two hospitalised patients and no separate data on courses of oral corticosteroids. There was no significant difference found in fatal or non‐fatal serious adverse events. Less inhaled and oral corticosteroids were used in the SiT group and the annual height gain was also greater in the SiT group. </p> </section> <section id="CD007313-sec-0095"> <h3 class="title" id="CD007313-sec-0095">Overall completeness and applicability of evidence</h3> <p>We found very little evidence in relation to the safety or efficacy of SiT in children, in whom the use of LABA is more contentious (<a href="./references#CD007313-bbs2-0032" title="BisgaardH . Effect of long‐acting Beta2 agonists on exacerbation rates of asthma in children. Pediatric Pulmonology2003; Vol. 36, issue 5:391‐8. [1099‐0496] ">Bisgaard 2003</a>). There is also no separate reporting of results from adolescents in any of the trials of adults and adolescents. </p> <p>It is possible that the difference between the results in trials comparing SiT with current best practice as opposed to higher doses of ICS alone as a comparison arm could relate to the design of the trials. Around 80% of the patients in the control arm of the current best practice trials were taking LABA, whereas none of the control arm patients in the higher dose maintenance ICS were taking LABA (as they were withdrawn from those patients previously using them). Further information will also be available in the review comparing SiT with combination therapy in double‐blind randomised trials (<a href="./references#CD007313-bbs2-0037" title="CatesCJ , LassersonTJ . Combination formoterol and inhaled steroid as maintenance and reliever therapy versus higher dose combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009019] ">Cates 2011</a>) </p> <p>The inclusion of patients who were symptomatic during run‐in periods in which LABA was withdrawn may favour SiT, as formoterol would be expected to control symptoms more quickly than ICS in <a href="./references#CD007313-bbs2-0006" title="ScicchitanoR , AalbersR , UkenaD , ManjraA , FouquertL , CentannS , et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research and Opinion2004;20(9):1403‐18. ">Scicchitano 2004</a>, <a href="./references#CD007313-bbs2-0012" title="Astrazenca(SD‐039‐0667) . Efficacy and safety of Symbicort® Turbuhaler® as single therapy in patients with mild to moderate asthma ‐ STEAM (SD‐039‐0667). Astrazeneca Clinical Trials Register2005:http://www.astrazenecaclinicaltrials.com (accessed 20th February 2008). RabeKF , PizzichiniE , StallbergB , RomeroS , BalanzatAM , AtienzaT , et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild‐to‐moderate asthma: A randomized, double‐blind trial. Chest2006;129:245‐56. ">STEAM</a>, <a href="./references#CD007313-bbs2-0010" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal.2001; Vol. 18, issue Suppl 33:517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001; Vol. 18, issue Suppl 33:331s. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004:Poster J93. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Adults</a> and <a href="./references#CD007313-bbs2-0011" title="BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy ‐ a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy and Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. American Journal of Respiratory and Critical Care Medicine2005;171(2):129‐36. SD‐039‐673 . Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as single therapy in patients with mild‐moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http://www.astrazenecaclinicaltrials.com2006. ">STAY ‐ Children</a>. The plots of individual patient exacerbations show steeper gradients initially for the budesonide arms of these trials but similar gradients in the two groups towards the end of the study period. </p> <p>This implies that the current evidence comparing SiT with fixed doses of ICS may only be directly applicable to patients who become symptomatic when maintenance treatment with ICS (with or without LABA) is reduced. How these results should be extrapolated to other groups of patients remains a matter for debate. </p> <p>Interpretation of the results of the studies comparing SiT with current best practice is not straightforward, as the compliance with ICS in the current best practice groups and the SiT groups was based on self‐reporting in a patient note‐book. The lower dose of ICS prescribed in the SiT arms may, therefore, not reflect the true difference in the ICS doses that were actually taken by the participants. </p> </section> <section id="CD007313-sec-0096"> <h3 class="title" id="CD007313-sec-0096">Quality of the evidence</h3> <p>For key outcomes relating to exacerbations, we regarded the risk of detection bias in studies comparing SiT against best practice to be sufficient to downgrade the quality of evidence. Taken with varying degrees of statistical imprecision, we have downgraded to either low or moderate quality evidence for hospital admissions and steroid‐treated exacerbations. In contrast the blinded design of the studies comparing SiT against higher doses of ICS protected the studies against detection bias in our view. The quality of evidence for a reduction in the exacerbations was therefore higher for this comparison. </p> </section> <section id="CD007313-sec-0097"> <h3 class="title" id="CD007313-sec-0097">Agreements and disagreements with other studies or reviews</h3> <p>A meta‐analysis of six of the trials (<a href="./references#CD007313-bbs2-0001" title="AstraZeneca(D5890L00011) . A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as‐needed) and conventional best practice for the treatment of persistent asthma in adults ‐ a 26‐week, randomised, open‐label, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/D5890L00011 Accessed December 12th 2012. [NCT00252863] ">DE‐SOLO</a>; <a href="./references#CD007313-bbs2-0002" title="AstraZeneca(D5890L00008) . MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00242411 [Accessed 12/04/2006]. ">MONO</a>; <a href="./references#CD007313-bbs2-0005" title="AstraZeneca(D5890L00009) . SALTO ‐ symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. www.clinicaltrials.gov2006:http://www.clinicaltrials.gov/ct/show/NCT00290264 [Accessed 22/02/2008]. ">SALTO</a>; <a href="./references#CD007313-bbs2-0007" title="SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiR , SmiljanicGeorijevN , et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice a randomised real life study. European Respiratory Journal2006;28(Suppl 50):613s. SearsMR , BouletL‐P , LavioletteM , FitzGeraldJM , BaiTR , KaplanA , et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. European Respiratory Journal2008:Epub: doi: 10.1183/09031936.00104007. ">SOLO</a>; <a href="./references#CD007313-bbs2-0013" title="AstraZeneca . STYLE ‐ A Comparison of Symbicort SMART (Symbicort Turbuhaler160/4,5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, open‐labelled, parallel‐group, multicentre study. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610702Accessed July 2012. [NCT00252824] AstraZeneca(D5890L00014) . STYLE ‐ symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. www.clinicaltrials.gov2005:http://www.clinicaltrials.gov/ct/show/NCT00252824 [Accessed 22/02/2008]. ">STYLE</a>; <a href="./references#CD007313-bbs2-0014" title="AstraZeneca . A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler 200/6 μg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26‐week, randomised, open, parallel group multicentre study. [D5890L00005]. http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical‐trials/resources/pdf/8610675Accessed July 2012. [NCT00259792] ">SYMPHONIE</a>) comparing SiT with current best practice was published before the 2013 update of this review and the findings for hospitalisation due to exacerbations, courses of oral steroids and time to first exacerbation were very similar to the findings of the updated review (<a href="./references#CD007313-bbs2-0041" title="DemolyP , LouisR , Soes‐PetersenU , NayaI , CarlsheimerA , WorthH , et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respiratory Medicine2009;103(11):1623‐32. ">Demoly 2009</a>). </p> <p>We agree with the reservations voiced by <a href="./references#CD007313-bbs2-0050" title="LipworthBJ , JacksonC . A SMART choice for primary care asthma therapy?. http://www.bmj.com/cgi/eletters/335/7618/513#178078 13 October 2007. ">Lipworth 2008</a> in his response in the <i>BMJ</i> to the review of single inhaler by <a href="./references#CD007313-bbs2-0031" title="BarnesPJ . Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. BMJ2007; Vol. 335, issue 7618:513. ">Barnes 2007</a>. Lipworth comments that the run‐in for the trials comparing SiT with fixed dose ICS was designed to select patients who became symptomatic when their maintenance treatment was reduced or when LABA were withdrawn. This feature of the trial design may contribute to the improvement in time to first asthma exacerbation on SiT, because the onset of action of higher dose ICS would be expected to be slower, and more patients may therefore have suffered an early exacerbation in the higher dose ICS arm of the trials. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007313-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007313-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Conventional Best Practice, outcome: 1.1 Patients with exacerbations causing hospitalisation." data-id="CD007313-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Adults and Adolescents treated with Single Inhaler Therapy versus Conventional Best Practice, outcome: 1.1 Patients with exacerbations causing hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 adults and adolescents treated with Single Inhaler Therapy versus Conventional Best Practice, outcome: 1.2 Patients with exacerbations treated with oral steroids." data-id="CD007313-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 adults and adolescents treated with Single Inhaler Therapy versus Conventional Best Practice, outcome: 1.2 Patients with exacerbations treated with oral steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="In the current best practice group 7 people out of 100 had exacerbations treated with oral steroids over 6 months, compared to 6 (95% CI 5 to 7) out of 100 for the single inhaler therapy group. NNT(B) = 90, (95% CI: 51 to 767)." data-id="CD007313-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>In the current best practice group 7 people out of 100 had exacerbations treated with oral steroids over 6 months, compared to 6 (95% CI 5 to 7) out of 100 for the single inhaler therapy group. NNT(B) = 90, (95% CI: 51 to 767). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus higher fixed dose ICS, outcome: 2.1 Patients with exacerbations causing hospitalisation." data-id="CD007313-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Adults and Adolescents treated with Single Inhaler Therapy versus higher fixed dose ICS, outcome: 2.1 Patients with exacerbations causing hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 adults and adolescents treated with Single Inhaler Therapy versus higher fixed dose ICS, outcome: 2.2 Patients with exacerbations treated with oral steroids." data-id="CD007313-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 adults and adolescents treated with Single Inhaler Therapy versus higher fixed dose ICS, outcome: 2.2 Patients with exacerbations treated with oral steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="In the fixed dose ICS group 18 people out of 100 had exacerbation treated with oral steroids over 11 months, compared to 11 (95% CI 9 to 12) out of 100 treated with single inhaler therapy. NNT(B) = 14, (95% CI 12 to 18)." data-id="CD007313-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>In the fixed dose ICS group 18 people out of 100 had exacerbation treated with oral steroids over 11 months, compared to 11 (95% CI 9 to 12) out of 100 treated with single inhaler therapy. NNT(B) = 14, (95% CI 12 to 18). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 1 Patients with exacerbations causing hospitalisation." data-id="CD007313-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 1 Patients with exacerbations causing hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 2 Patients with exacerbations treated with oral steroids." data-id="CD007313-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 2 Patients with exacerbations treated with oral steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 3 Fatal serious adverse events (fatal)." data-id="CD007313-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 3 Fatal serious adverse events (fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 4 Serious adverse events (non‐fatal)." data-id="CD007313-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 4 Serious adverse events (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 5 Discontinuation due to adverse events." data-id="CD007313-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 5 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt='Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 6 Patients with "severe" exacerbation (time to event).' data-id="CD007313-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 6 Patients with "severe" exacerbation (time to event). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 7 Change in PEF (% predicted)." data-id="CD007313-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 7 Change in PEF (% predicted). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 8 Rescue medication use (puffs per day)." data-id="CD007313-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 8 Rescue medication use (puffs per day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 9 Quality of Life (change in ACQ score)." data-id="CD007313-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 9 Quality of Life (change in ACQ score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 10 ICS dose (micrograms per day)." data-id="CD007313-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice, Outcome 10 ICS dose (micrograms per day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 1 Patients with exacerbations causing hospitalisation." data-id="CD007313-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 1 Patients with exacerbations causing hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 2 Patients with exacerbations treated with oral steroids." data-id="CD007313-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 2 Patients with exacerbations treated with oral steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 3 Serious adverse events (fatal)." data-id="CD007313-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 3 Serious adverse events (fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 4 Serious adverse events (non‐fatal)." data-id="CD007313-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 4 Serious adverse events (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 5 Discontinuation due to adverse events." data-id="CD007313-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 5 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 6 ICS dose (micrograms per day BDP equivalent)." data-id="CD007313-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care, Outcome 6 ICS dose (micrograms per day BDP equivalent). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 1 Patients with exacerbations causing hospitalisation." data-id="CD007313-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 1 Patients with exacerbations causing hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-003-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 2 Patients with exacerbations treated with oral steroids." data-id="CD007313-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 2 Patients with exacerbations treated with oral steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 3 Fatal serious adverse events." data-id="CD007313-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 3 Fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 4 Serious adverse events (non‐fatal)." data-id="CD007313-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 4 Serious adverse events (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 5 Discontinuation due to adverse events." data-id="CD007313-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 5 Discontinuation due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt='Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 6 Patients with "severe" exacerbation (time to event).' data-id="CD007313-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 6 Patients with "severe" exacerbation (time to event). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 7 PEF (Litres/min)." data-id="CD007313-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 7 PEF (Litres/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 8 FEV1 increase (Litres)." data-id="CD007313-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 8 FEV<sub>1</sub> increase (Litres). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 9 Rescue medication use (puffs per day)." data-id="CD007313-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 9 Rescue medication use (puffs per day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 10 Quality of Life (fall in ACQ score)." data-id="CD007313-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Adults using BDF single inhaler therapy versus fixed dose ICS, Outcome 10 Quality of Life (fall in ACQ score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 1 Patients with exacerbations causing hospitalisation." data-id="CD007313-fig-0034" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 1 Patients with exacerbations causing hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 2 Fatal serious adverse events." data-id="CD007313-fig-0035" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 2 Fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 3 Serious adverse events (non‐fatal)." data-id="CD007313-fig-0036" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 3 Serious adverse events (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 4 Annual height gain (cms)." data-id="CD007313-fig-0037" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 4 Annual height gain (cms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 5 Children with low plasma cortisol (&lt;400 nmol/L)." data-id="CD007313-fig-0038" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 5 Children with low plasma cortisol (&lt;400 nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 6 Patients with an exacerbation requiring increase in ICS or other treatment." data-id="CD007313-fig-0039" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 6 Patients with an exacerbation requiring increase in ICS or other treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 7 Change in morning PEF (L/min)." data-id="CD007313-fig-0040" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 7 Change in morning PEF (L/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 8 Change in clinic FEV1 (Litres)." data-id="CD007313-fig-0041" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 8 Change in clinic FEV<sub>1</sub> (Litres). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 9 As‐needed medication use over 24 hours." data-id="CD007313-fig-0042" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 9 As‐needed medication use over 24 hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007313-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/urn:x-wiley:14651858:media:CD007313:CD007313-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_t/tCD007313-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 10 Nocturnal awakenings." data-id="CD007313-fig-0043" src="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS, Outcome 10 Nocturnal awakenings. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/media/CDSR/CD007313/image_n/nCD007313-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007313-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">160/4.5 mcg BDF single inhaler therapy compared to current best practice for adult asthma that is not controlled on ICS</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>160/4.5</b> µg<b>BDF single inhaler therapy compared to current best practice for adults with asthma that is not controlled on ICS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with asthma that is not controlled on ICS<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> 160/4.5 µg BDF single inhaler therapy<br/> <b>Comparison:</b> current best practice </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Current best practice</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> 160/4.5 µgBDF single inhaler therapy </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations causing hospitalisation</b> <br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/> (3 to 8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.81</b> <br/> (0.45 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8841<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations treated with oral steroids</b> <br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> <br/> (50 to 69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.83</b> <br/> (0.70 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8841<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatal serious adverse events</b> <br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> <br/> (0 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.95</b> <br/> (0.53 to 7.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8841<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (non‐fatal)</b> <br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> <br/> (18 to 32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.20</b> <br/> (0.90 to 1.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8841<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Discontinuation due to adverse events</b> <br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> <br/> (14 to 31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.85</b> <br/> (1.89 to 4.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8411<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Unblinded trials<br/> <sup>2</sup> Confidence interval cannot rule out important differences in either direction </p> <p>BDF: budesonide plus formoterol; ICS: inhaled corticosteroids</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">160/4.5 mcg BDF single inhaler therapy compared to current best practice for adult asthma that is not controlled on ICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007313-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Single inhaler therapy compared to fixed dose ICS for asthma in adults not controlled on regular ICS</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Single inhaler therapy compared to fixed dose ICS for asthma in adults not controlled on regular ICS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with asthma in adults not controlled on regular ICS<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> Single inhaler therapy<br/> <b>Comparison:</b> fixed dose ICS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fixed dose ICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Single inhaler therapy </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations causing hospitalisation</b> <br/> Follow‐up: mean 11 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (3 to 11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.56</b> <br/> (0.28 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4209<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with exacerbations treated with oral steroids</b> <br/> Follow‐up: mean 11 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>107 per 1000</b> <br/> (90 to 124) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.54</b> <br/> (0.45 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4280<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatal serious adverse events</b> <br/> Follow‐up: mean 11 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> <br/> (0 to 4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.37</b> <br/> (0.05 to 2.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4209<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (non‐fatal)</b> <br/> Follow‐up: mean 11 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> <br/> (36 to 62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.97</b> <br/> (0.73 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4209<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Discontinuation due to adverse events</b> <br/> Follow‐up: mean 11 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> <br/> (13 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.57</b> <br/> (0.35 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2586<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Confidence interval cannot rule out important differences in either direction<br/> ICS: inhaled corticosteroids </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Single inhaler therapy compared to fixed dose ICS for asthma in adults not controlled on regular ICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/full#CD007313-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007313-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Patients with exacerbations causing hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.45, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Patients with exacerbations treated with oral steroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.70, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fatal serious adverse events (fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.53, 7.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.90, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [1.89, 4.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Patients with "severe" exacerbation (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.85, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in PEF (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Rescue medication use (puffs per day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Quality of Life (change in ACQ score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 ICS dose (micrograms per day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 ICS as prescribed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 BDP equivalent doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adults using 160/4.5 mcg BDF single inhaler therapy versus current best practice</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007313-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Patients with exacerbations causing hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Patients with exacerbations treated with oral steroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events (fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 ICS dose (micrograms per day BDP equivalent) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adults using 80/4.5 mcg BDF single inhaler therapy versus usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007313-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adults using BDF single inhaler therapy versus fixed dose ICS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Patients with exacerbations causing hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.28, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Single inhaler therapy versus higher dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.28, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Patients with exacerbations treated with oral steroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.45, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Single inhaler therapy versus higher dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.44, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Single inhaler therapy versus same dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.29, 6.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.05, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Single inhaler therapy versus higher dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.05, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Single inhaler therapy versus higher dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.35, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Single inhaler therapy versus higher dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.35, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Patients with "severe" exacerbation (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.49, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Single inhaler therapy versus higher dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.49, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 PEF (Litres/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.29 [17.62, 26.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Single inhaler therapy versus higher dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.29 [17.62, 26.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 FEV<sub>1</sub> increase (Litres) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.07, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Single inhaler therapy versus higher dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.08, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Single inhaler therapy versus same dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.19, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Rescue medication use (puffs per day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.49, ‐0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Single inhaler therapy versus higher dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.49, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Quality of Life (fall in ACQ score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Single inhaler therapy versus same dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adults using BDF single inhaler therapy versus fixed dose ICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007313-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Patients with exacerbations causing hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Annual height gain (cms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Children with low plasma cortisol (&lt;400 nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Patients with an exacerbation requiring increase in ICS or other treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in morning PEF (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change in clinic FEV<sub>1</sub> (Litres) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 As‐needed medication use over 24 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Nocturnal awakenings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Children using 80/4.5 mcg BDF single inhaler therapy versus higher fixed dose ICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007313.pub3/references#CD007313-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007313.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007313-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007313-note-0006">فارسی</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007313\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007313\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007313\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007313\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007313\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tlnpj831&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007313.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007313.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007313.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007313.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007313.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726983162"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007313.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726983166"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007313.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea0f208bdf401',t:'MTc0MDcyNjk4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 